Results 61 to 70 of about 34,736 (209)
Post‐Translational Regulation of CD8+ T Cell Fate and Dysfunction in Tumor Immunity
Advanced Science, EarlyView.This review delineates how post‐translational modifications (PTMs) function as a central regulatory interface governing CD8+ T cell activation, differentiation, persistence, and exhaustion in antitumor immunity. By integrating antigenic, metabolic, and microenvironmental cues, diverse PTM programs coordinate transcriptional and chromatin states that ...
Zihao Zhou +8 more
wiley +1 more source
Кардиоваскулярная терапия и профилактика, 2017 Aim. To assess the level of galectin-3 in blood serum of metabolic syndrome patients (MS), with heart failure (CHF).Material and methods. Totally, 43 patients investigated, with MS, and of those 37 CHF patients and 33 on-CHF, of those 17 had CHF ...
O. M. Drapkina +2 more
doaj +1 more source
Mucin Glycoprotein Nanoparticles Enable a Selective Antisense Therapy for Oncogenic MicroRNAs
Advanced NanoBiomed Research, EarlyView.Mucin glycoproteins are turned into nanoparticles by employing synthetic DNA strands, which have a dual function: they stabilize the nanoparticles and act as binding sites for intracellular miRNA‐21. Thus, upon internalization into tumor cells, these mucin nanoparticles can deplete miRNA‐21 from the cytosol, which induces apoptosis in vitro and in vivo.
Ceren Kimna +9 more
wiley +1 more source
Arthritis &Rheumatology, EarlyView.Interlukin‐5 (IL‐5) plays a crucial role in the pathogenesis of eosinophilic granulomatosis with polyangiitis (EGPA) by promoting eosinophil differentiation, activation, and survival. We present here a typical case of EGPA in which treatment with IL‐5 pathway inhibitors is prescribed, showing to be beneficial for the patient.
Alvise Berti, Christian Pagnoux
wiley +1 more source
Arthritis &Rheumatology, Accepted Article.Objective Rituximab, a CD20+ B cell depletion therapy, is frequently used to treat systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation.
Haerin Jang +9 more
wiley +1 more source
Galectin-3 as a marker and potential therapeutic target in breast cancer. [PDF]
PLoS ONE, 2014 Galectin-3 has a relatively high level of expression in triple-negative breast cancers and is a potential marker for this disease. However, the clinical and prognostic implications of galectin-3 expression in breast cancer remain unclear.
Hao Zhang +10 more
doaj +1 more source
BMEMat, EarlyView.This Perspective explores the emerging landscape of cell membrane‐coated nanoparticles (CM‐NPs) as intelligent, immune‐compatible platforms for cancer therapy. Highlighting design strategies, translational challenges, and competitive positioning, it outlines how integrating biomimetic targeting with advanced analytical and manufacturing tools could ...
A. K. M. M. Alam +4 more
wiley +1 more source
Biomarkers of lung congestion and injury in acute heart failure
ESC Heart Failure, Volume 12, Issue 2, Page 781-789, April 2025.Abstract Acute heart failure (AHF) classification and management are primarily based on lung congestion and/or hypoperfusion. The quantification of the vascular and tissue lung damage is not standard practice though biomarkers of lung injury may play a relevant role in this context.
Marco Guazzi +9 more
wiley +1 more source
Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy
ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo +7 more
wiley +1 more source
Indian Pacing and Electrophysiology Journal, 2020 Background: Serum galectin-3, a circulating biomarker of fibrosis, has been associated with atrial remodelling. Recent studies investigating serum galectin-3 and AF recurrence post-ablation have shown mixed results.
Raymond Pranata +4 more
doaj +1 more source